Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Liberty G Sieberg"'
Autor:
Catherine Langston, Joshua B. Daniels, Paul J. Lunghofer, Kristy L. Dowers, Daniel L. Gustafson, Liberty G Sieberg, Kellyi K Benson, Jessica M Quimby
Publikováno v:
Journal of Feline Medicine and Surgery. 22:729-735
Objectives The aims of this study were to determine the side effect frequency and serum and urine drug concentrations of amoxicillin–clavulanic acid in cats with and without azotemic chronic kidney disease (azCKD). Methods Owners whose cats had bee
Autor:
Jessica M Quimby, Liberty G Sieberg
Publikováno v:
Journal of Feline Medicine and Surgery. 22:539-543
Objectives The aim of this study was to assess the effect of three oral potassium supplements (potassium gluconate tablets [PGT], potassium gluconate granules [PGG] and potassium citrate granules [PCG]) on hypokalemia and serum bicarbonate in cats wi
Autor:
Jessica M Quimby, Rikki L. Fitzpatrick, Dominique Ramirez, Liberty G Sieberg, Kellyi K Benson, Daniel L. Gustafson, Luke Anthony Wittenburg
Publikováno v:
Journal of veterinary internal medicine, vol 32, iss 6
Journal of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine
Background Liver disease (LD) prolongs mirtazapine half‐life in humans, but it is unknown if this occurs in cats with LD and healthy cats. Hypothesis/Objectives To determine pharmacokinetics of administered orally mirtazapine in vivo and in vitro (
Publikováno v:
Journal of Feline Medicine and Surgery. 20:884-890
Objectives The purpose of this study was to survey owners regarding their practices and experiences with the administration of subcutaneous (SC) fluids at home to cats with chronic kidney disease (CKD) to gain insight that might help more owners be s
Autor:
Amber L Caress, Jessica M Quimby, Andrea K Herndon, Sabina Ligas, Leigh Davis, Liberty G Sieberg, Danial L Gustafson, Luke Anthony Wittenburg, Ryan J. Hansen
Publikováno v:
Journal of Feline Medicine and Surgery. 20:721-727
Objectives The objectives were to evaluate the pharmacokinetics (PK) of subcutaneous (SC) and intravenous (IV) dolasetron and the pharmacodynamics (PD) of SC dolasetron in healthy cats. Methods Five cats with unremarkable complete blood count, serum